BNP Paribas Financial Markets
AARD

BNP Paribas Financial Markets’s Aardvark Therapeutics AARD Stock Holding History

BNP Paribas Financial Markets’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.53K Sell
1,308
-1,926
-60% -$9K ﹤0.01% 5415
2026
Q1 		$12.2K Sell
3,234
-12,622
-80% -$131K ﹤0.01% 5181
2025
Q4 		$208K Sell
15,856
-40,690
-72% -$508K ﹤0.01% 4040
2025
Q3 		$751K Buy
56,546
+21,052
+59% +$237K ﹤0.01% 3328
2025
Q2 		$480K Buy
35,494
+804
+2% +$8.29K ﹤0.01% 3345
2025
Q1 		$261K Buy
+34,690
New +$390K ﹤0.01% 3565

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

BNP Paribas Financial Markets's AARD Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Aardvark Therapeutics (AARD) stake by 60% in Q2 2026, selling an estimated $9K and leaving 1,308 shares worth $7.53K. The position accounts for ﹤0.01% of the portfolio, ranked #5415.

BNP Paribas Financial Markets first reported a position in AARD in Q1 2025 and has held it in 6 quarters since. The position peaked at $751K in Q3 2025. 71 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

  • BNP Paribas Financial Markets held 1,308 shares of Aardvark Therapeutics worth $7.53K as of Q2 2026.
  • BNP Paribas Financial Markets sold 1,926 Aardvark Therapeutics shares in Q2 2026, an estimated $9K.
  • Aardvark Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #5415 holding.
  • BNP Paribas Financial Markets first reported a position in Aardvark Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • BNP Paribas Financial Markets's Aardvark Therapeutics position peaked at $751K in Q3 2025.
  • 71 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.